Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131623 · ClinicalTrials.gov registry record
Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
A clinical trial, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- 23
- Enrollment target
NCT02131623: Completed study, sponsored by Mirum Pharmaceuticals.
NCT02131623 is a clinical trial that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02131623 has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of the study is to validate the ItchRO instrument (a clinical outcome assessment measure of itching) prior to the analysis of longitudinal treatment effect data being generated in ongoing clinical trials.
Primary Outcome
Validate the ItchRO measure with subjects with Alagille Syndrome (ALGS) or Progressive Familial Intrahepatic Cholestasis (PFIC) and/or their caregivers through the completion of the electronic diary twice daily over the course of two weeks.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
What the finished NCT02131623 record still lists
NCT02131623 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02131623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02131623 about?
NCT02131623 is a clinical study titled "Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease". The purpose of the study is to validate the ItchRO instrument (a clinical outcome assessment measure of itching) prior to the analysis of longitudinal treatment effect data being generated in ongoing clinical trials.
What is the current status of trial NCT02131623?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2014-07. Estimated completion is 2015-03.
Who is sponsoring clinical trial NCT02131623?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia